Evidence map›Paper›PMID 42488567›Full record

ArticleFrontiers in pharmacology2026

Chinese prescription Kangen-karyu attenuates neuronal damage and improves cognitive function in global cerebral ischemia/reperfusion by regulating ROS-mediated MAPK activation.

Ji Hyeon Lee, Jong-Tae Kim, Sung Woo Han, Seongwon Pak, Seonju Lee, Yeonwoo Cho, Yoshie Akimoto, Masahiro Shoji, Liye Zhang, Kang Song and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ji Hyeon Lee *Institute of New Frontier Research Team, Research Institute of Medical-Bio Convergence, Hallym University, Chuncheon, Republic of Korea.
Jong-Tae Kim *Institute of New Frontier Research Team, Research Institute of Medical-Bio Convergence, Hallym University, Chuncheon, Republic of Korea.
Sung Woo HanInstitute of New Frontier Research Team, Research Institute of Medical-Bio Convergence, Hallym University, Chuncheon, Republic of Korea.
Seongwon PakAsan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Seonju LeeInstitute of New Frontier Research Team, Research Institute of Medical-Bio Convergence, Hallym University, Chuncheon, Republic of Korea.
Yeonwoo ChoInstitute of New Frontier Research Team, Research Institute of Medical-Bio Convergence, Hallym University, Chuncheon, Republic of Korea.
Yoshie AkimotoIskra Industry Co., Ltd., Chuo, Japan.
Masahiro ShojiPharmacy of Kaikido, Yokohama, Japan.
Liye ZhangIskra Industry Co., Ltd., Chuo, Japan.
Kang SongBio and Health Photonics Research Center Korea Photonics Technology Institute, Cheonan, Republic of Korea.
Hae Ryong ChoiBio and Health Photonics Research Center Korea Photonics Technology Institute, Cheonan, Republic of Korea.
Gui Seung HanLife Genomics Co., Ltd., Ressearch and Development Center, Suwon, Republic of Korea.
Hae Young ChungDepartment of Pharmacy, College of Pharmacy, Pusan National University, Busan, Republic of Korea.
Jae Sue ChoiDepartment of Food Science and Human Nutrition, Chongbuk National University, Jeonju, Republic of Korea.
Jung Dae LimDepartment of Bio-Health Convergence, Kangwon National University, Chuncheon, Republic of Korea.
Jin Pyeong JeonDepartment of Neurosurgery, College of Medicine, Hallym University, Chuncheon, Republic of Korea.
Chan Hum ParkInstitute of New Frontier Research Team, Research Institute of Medical-Bio Convergence, Hallym University, Chuncheon, Republic of Korea.
Dong Hyuk Youn *Institute of New Frontier Research Team, Research Institute of Medical-Bio Convergence, Hallym University, Chuncheon, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Global cerebral ischemia is a well-established experimental model for studying hippocampal vulnerability and memory impairment. This study investigated the neuroprotective potential of Kangen-karyu (KK) in a mouse model of global cerebral ischemia/reperfusion injury induced by bilateral common carotid artery occlusion (BCCAO). Methods: Male C57BL/6J mice were subjected to BCCAO followed by reperfusion. KK or nimodipine was administered orally either before or after ischemia. Neurological outcomes, histopathology, and markers of oxidative stress, inflammation, and apoptosis were evaluated. Results: Post-ischemic administration of KK significantly reduced brain edema, neuronal degeneration, and ischemia/reperfusion-induced brain damage, while improving cognitive performance. These effects were associated with decreased phosphorylation of JNK/p38 MAPK and reduced expression of iNOS and apoptosis-related proteins. Post-treatment produced greater benefits than pre-treatment or nimodipine. Conclusion: KK may have therapeutic potential for mitigating global cerebral ischemia/reperfusion-induced brain injury, possibly through modulation of stress- and inflammation-related pathways. Further studies are warranted to validate these findings.

Indexed as

bilateral common carotid artery occlusioncognitionglobal cerebral ischemia/reperfusionJNK/p38Kangen-karyuneuroprotective

Identifiers

PMID42488567
PMCPMC13388890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.